Überall MA, Elling C, Eibl C, et al. Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry [published online ahead of print, 2021 Aug 11]. Pain Manag. 2021;10.2217/pmt-2021-0058. doi:10.2217/pmt-2021-0058

Zah V, Brook?eld RB, Imro M, Tatovic S, Pelivanovic J, Vukicevic D. Healthcare Costs And Resource Utilization In Chronic Pain Patients Treated With Extended-Release Formulations Of Tapentadol, Oxycodone, Or Morphine Stratified By Type Of Pain: A Retrospective Claims Analysis, 2012-2016. J Pain Res. 2019;12:3037?3048. Published 2019 Nov 8. doi:10.2147/JPR.S222617

Thakur D, Dickerson S. Response to letter received from Moore and Schug: Thakur et al. Impact of Prolonged-Release Oxycodone/Naloxone on Outcomes Affecting Patients? Daily Functioning in Comparison With Extended-Release Tapentadol: A Systematic Review. Clin Ther. 2015;37(8):1867-1868. doi:10.1016/j.clinthera.2015.05.500

Coluzzi F, Ruggeri M. Comparing tapentadol to oxycodone/naloxone combination: imagining castles in the air?…?while building sandcastles! Re: Coluzzi F, Ruggeri M. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr Med Res Opin 2014;30:1139-51. Curr Med Res Opin. 2015;31(2):339-342. doi:10.1185/03007995.2014.971361